Ticagrelor Market To Find Better Growth with US$ 3.2 Billion By 2026 | CAGR: 12.3%: Coherent Market Insights
Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Global Ticagrelor Market, by Strength (60 mg and 90 mg), by Indication (Acute Coronary Syndrome and Ischemic Stroke), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) was valued at US$ 1,145.0 million in 2017, and is expected to exhibit a CAGR of 12.3% over the forecast period (2018 – 2026) as highlighted in a new report published by .
Ticagrelor is an antiplatelet drug, which is used as an agent to reduce stent thrombosis. The major factors that are expected to drive growth of the ticagrelor market include rising number of patients suffering from heart problems, increasing launches of generic drug versions, and improvement in market scenarios, attributed to increasing funding for research and development by key players in the market.
Browse Research Report At: https://www.coherentmarketinsights.com/market-insight/ticagrelor-market-2515
The increasing incidence of heart diseases is expected to drive adoption of ticagrelor, which is further expected to propel growth of the ticagrelor market over the forecast period. For instance, according to the Centers for Disease Control and Prevention 2015, around 610,000 people are reported to die due to heart disease in the U.S. every year and cardiovascular diseases is the major cause of deaths, globally.
Browse 23 Market Data Tables and 19 Figures spread through 157 Pages and in-depth TOC on “Ticagrelor Market, by Strength (60 mg and 90 mg), by Indication (Acute Coronary Syndrome, and Ischemic Stroke), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) – Global Forecast to 2026”
To know the latest trends and insights related to Ticagrelor market press release, click the link below: https://www.coherentmarketinsights.com/press-release/ticagrelor-market-to-surpass-us-32-billion-by-2026-1305
Additionally, manufacturers are focused on increasing research and development activities for new drug approvals. For instance, in March 2015, the U.S. Food and Drug Administration (USFDA) approved Brilinta tablet (ticagrelor) for acute coronary syndrome (ACS) patients, who are unable to swallow Brilinta 90 mg tablets as a whole. With this approval, Brilinta can be consumed by crushing the tablet and administered in water by swallowing or via nasogastric tube.
Furthermore, in September 2015, the U.S. FDA approved Brilinta (ticagrelor) tablets manufactured by AstraZeneca plc, 60mg dose to be used in patients with a history of heart attack. With this expanded indication, Brilinta was approved to reduce the rate of cardiovascular deaths and myocardial infarction.
Moreover, increasing generic drugs approvals by regulatory bodies is expected to propel growth of the ticagrelor market over the forecast period. For instance, Alembic Pharmaceuticals, received tentative approval from the U.S. FDA for ticagrelor tablets in 90 mg strength, in July 2018, in order to reduce the rate of cardiovascular deaths and strokes in patients with acute coronary syndrome or a history of myocardial infarction.
We value your investment and offer customization as per your requirements.
Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/2515
Key Takeaways of the Ticagrelor Market:
- The global ticagrelor market is expected to exhibit a CAGR of 12.3% over the forecast period (2018-2026), attributed to increasing mergers and acquisitions by key players
- On the basis of strength, 90 mg segment is expected to hold a dominant position in the global market over the forecast period, attributed to new marketing strategies adopted by key players. For instance, in June 2015, Sun Pharmaceutical Industries and AstraZeneca Pharma India entered into a distribution services agreement in India for AstraZeneca’s brand Axcer, a new brand of ticagrelor with 90 mg strength, indicated for the treatment of acute coronary syndrome (ACS). Such organic growth strategies adopted by key players are expected to augment growth of the ticagrelor market during the forecast period.
- Key players operating in the global ticagrelor market include C.H. Boehringer Sohn AG & Ko. KG, Pfizer Inc., Eli Lilly and Company, AstraZeneca plc, Natco Pharma Limited, Anhui Haikang Pharmaceutical Co., Ltd., Avra Laboratories Pvt. Ltd., and Sun Pharmaceutical Industries Ltd.
Apply Promo Code “STAYHOME” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2515
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire